Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diperoxochloric Acid
Therapeutic Area : Podiatry
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer
Details : WOXheal has dual mechanism of action, i.e. it has functional antibacterial action against Gram positive and gram negative bacteria and it also promotes growth of fibroblast cells, thereby yielding complete wound closure.
Brand Name : WOXheal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2020
Lead Product(s) : Diperoxochloric Acid
Therapeutic Area : Podiatry
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VXA-CoV2-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Vaxart
Deal Size : Undisclosed
Deal Type : Agreement
KindredBio Expands Manufacturing Agreement with Vaxart
Details : The manufacturing services will be performed via Centaur Biopharmaceutical Services (Centaur), a wholly owned subsidiary of KindredBio that provides full service contract development and manufacturing services.
Brand Name : VXA-CoV2-1
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 07, 2020
Lead Product(s) : VXA-CoV2-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Vaxart
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
